Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analyst Says FDA First-Line Approval Of Takeda/Millennium’s Velcade No Surprise

This article was originally published in PharmAsia News

Executive Summary

TOKYO - The U.S. FDA's approval of Millennium Pharmaceuticals' Velcade (bortezomib) injection indicated for first-line treatment of multiple myeloma comes as no surprise to those analyzing the pharmaceutical industry
Advertisement

Related Content

Takeda Copes With FDA Delays, Yen Appreciation and Acquisition Drags in 2008
Takeda Faces Serial FDA Delays, Yen Appreciation And Acquisition Drags In 2008
Takeda Faces Serial FDA Delays, Yen Appreciation And Acquisition Drags In 2008
Takeda Copes With FDA Delays, Yen Appreciation and Acquisition Drags in 2008
Takeda Forecasts Loss for Fiscal 2008 After Flurry of M&A Moves
Takeda Forecasts Loss for Fiscal 2008 After Flurry of M&A Moves
Advertisement
UsernamePublicRestriction

Register

SC068815

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel